Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations.
Lynch DR, Perlman S, Schadt K.
Expert Rev Neurother · review; journal article · DOI 10.1080/14737175.2024.2310617 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för omaveloxolone. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
32 träffarOmaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
Pilotto F, Chellapandi DM, Puccio H.
Trends Mol Med · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.molmed.2023.12.002Omaveloxolone ameliorates isoproterenol-induced pathological cardiac hypertrophy in mice.
Li X, Wu Y, Yang Y, Wu Y, Yu X, Hu W.
Free Radic Res · journal article · DOI 10.1080/10715762.2023.2299359RTA 408 ameliorates diabetic cardiomyopathy by activating Nrf2 to regulate mitochondrial fission and fusion and inhibiting NF-κB-mediated inflammation.
Hao J, Zhou J, Hu S, Zhang P, Wu H, Yang J, Zhao B, Liu H, Lin H, Chi J, Lou D.
Am J Physiol Cell Physiol · research support, non-u.s. gov't; journal article · DOI 10.1152/ajpcell.00467.2023Omaveloxolone ameliorates cognitive dysfunction in APP/PS1 mice by stabilizing the STAT3 pathway.
Cui X, Zong S, Song W, Wang C, Liu Y, Zhang L, Xia P, Wang X, Zhao H, Wang L, Lu Z.
Life Sci · journal article · DOI 10.1016/j.lfs.2023.122261Correction to Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
Lynch D.
Ann Neurol · published erratum; correction · DOI 10.1002/ana.26808RTA-408 Regulates p-NF-κB/TSLP/STAT5 Signaling to Ameliorate Nociceptive Hypersensitivity in Chronic Constriction Injury Rats.
Lu YY, Tsai HP, Tsai TH, Miao HC, Zhang ZH, Wu CH.
Mol Neurobiol · journal article · DOI 10.1007/s12035-023-03660-wPropensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
Lynch DR, Goldsberry A, Rummey C, Farmer J, Boesch S, Delatycki MB, Giunti P, Hoyle JC, Mariotti C, Mathews KD, Nachbauer W, Perlman S, Subramony SH, Wilmot G, Zesiewicz T, Weissfeld L, Meyer C.
Ann Clin Transl Neurol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/acn3.51897NRF2 activation suppresses motor neuron ferroptosis induced by the SOD1<sup>G93A</sup> mutation and exerts neuroprotection in amyotrophic lateral sclerosis.
Yang B, Pan J, Zhang XN, Wang H, He L, Rong X, Li X, Peng Y.
Neurobiol Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.nbd.2023.106210Omaveloxolone.
Författaruppgift saknas
Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxad072Omaveloxolone: First Approval.
Lee A.
Drugs · review; journal article · DOI 10.1007/s40265-023-01874-9A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.
Subramony SH, Lynch DL.
Cerebellum · review; journal article · DOI 10.1007/s12311-023-01568-8Omaveloxolone (Skyclarys<sup>TM</sup>) for patients with Friedreich's ataxia.
Dayalan Naidu S, Dinkova-Kostova AT.
Trends Pharmacol Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.tips.2023.03.005Omaveloxolone
Författaruppgift saknas
Tidskrift saknas · reviewSynthetic oleanane triterpenoids suppress <i>MYB</i> oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy.
Tejera Nevado P, Tešan Tomić T, Atefyekta A, Fehr A, Stenman G, Andersson MK.
Front Oncol · research-article; journal article · DOI 10.3389/fonc.2023.1126354Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
Profeta V, McIntyre K, Wells M, Park C, Lynch DR.
Expert Opin Investig Drugs · journal article · DOI 10.1080/13543784.2023.2173063Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
Lynch DR, Chin MP, Boesch S, Delatycki MB, Giunti P, Goldsberry A, Hoyle JC, Mariotti C, Mathews KD, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot G, Zesiewicz T, Meyer CJ.
Mov Disord · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/mds.29286Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects.
Zighan M, Arkadir D, Douiev L, Keller G, Miller C, Saada A.
Front Mol Biosci · research-article; journal article · DOI 10.3389/fmolb.2022.890653In Vitro Efficacy and Molecular Mechanism of Curcumin Analog in Pathological Regulation of Spinocerebellar Ataxia Type 3.
Wu YL, Chang JC, Chao YC, Chan H, Hsieh M, Liu CS.
Antioxidants (Basel) · research-article; journal article · DOI 10.3390/antiox11071389Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model.
Cohen-Nowak AJ, Cohen AJ, Correia ED, Portocarrero CP, South AP, Nikbakht N.
Exp Dermatol · research support, non-u.s. gov't; journal article · DOI 10.1111/exd.14564Synthetic Triterpenoid RTA-408: Limits Radiation Damage to Normal Tissue.
Luginbuhl AJ, Hobelmann K, Rodin J, Shukla S, Rodeck U, Linnenbach A.
Laryngoscope · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1002/lary.29930Nrf2 Activation Attenuates Chronic Constriction Injury-Induced Neuropathic Pain via Induction of PGC-1<i>α</i>-Mediated Mitochondrial Biogenesis in the Spinal Cord.
Sun J, Li JY, Zhang LQ, Li DY, Wu JY, Gao SJ, Liu DQ, Zhou YQ, Mei W.
Oxid Med Cell Longev · research-article; journal article · DOI 10.1155/2021/9577874The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy.
Chien JY, Chien JY, Chien JY, Chou YY, Ciou JW, Liu FY, Huang SP.
Antioxidants (Basel) · research-article; journal article · DOI 10.3390/antiox10091466RTA-408 protects against propofol-induced cognitive impairment in neonatal mice via the activation of Nrf2 and the inhibition of NF-κB p65 nuclear translocation.
Zhang L, Zhou Q, Zhou CL.
Brain Behav · research-article; journal article · DOI 10.1002/brb3.1918Mechanisms and therapeutic implications of RTA 408, an activator of Nrf2, in subarachnoid hemorrhage-induced delayed cerebral vasospasm and secondary brain injury.
Tsai TH, Lin SH, Wu CH, Tsai YC, Yang SF, Lin CL.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0240122Nrf2 Activator RTA-408 Protects Against Ozone-Induced Acute Asthma Exacerbation by Suppressing ROS and γδT17 Cells.
Zhang JH, Yang X, Chen YP, Zhang JF, Li CQ.
Inflammation · journal article · DOI 10.1007/s10753-019-01046-6The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
Sun X, Xie Z, Hu B, Zhang B, Ma Y, Pan X, Huang H, Wang J, Zhao X, Jie Z, Shi P, Chen Z.
Redox Biol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.redox.2019.101309RTA 408 Inhibits Interleukin-1β-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent NF-κB and AP-1 Activation in Rat Brain Astrocytes.
Yang CC, Lin CC, Jou MJ, Hsiao LD, Yang CM.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms20112826Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto M, Ward KW.
Drug Des Devel Ther · clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.2147/dddt.s193889[Effect and related mechanisms of RTA-408 on rat vascular smooth muscle cell calcification induced by advanced glycation end products].
Xu Z, Suo CJ, Ruan YS, Tan RY, Zhang W, Niu TL.
Zhonghua Xin Xue Guan Bing Za Zhi · journal article · DOI 10.3760/cma.j.issn.0253-3758.2018.06.012